Drug
S243249
S243249: highest development phase Phase 1/2, developed by Servier. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Servier
Trials
| Drug | Phase | Indication |
|---|---|---|
| S243249 600mg NCT07722312 | Phase 1/2 | Relapsed or Refractory Acute Leukemia |
Latest
No recent events.
Follow S243249 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.